Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome

Publisher Website
Google Scholar
Abstract
Objectives: A high prevalence of associated metabolic cardiovascular risk factors is often observed among hypertensive subjects. The aim of the present study was to assess the effects of 1–2 mg/day of rilmenidine, a centrally acting antihypertensive agent with selectivity for I1 imidazoline receptors, vs. 2.5–5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome.Research design and methods: In this 6‐month multicentre, comparative, double-blind, parallel group study, the primary objective was to assess the effects of the treatments on blood pressure (BP); the secondary endpoints were to assess glucose and lipid metabolism, in addition to clinical and biological tolerability. In non-responder patients, dose adjustment was possible from the first month and adding a diuretic from the third month.Results: Of an intention-to-treat population of 93 patients, 84 per protocol patients completed the study: 42 in the rilme...